Pathological bases and clinical impact of long noncoding RNAs in prostate cancer: a new budding star

Xu, Tao; Lin, Chang-Ming; Cheng, Shu-qi; Min, Jie; Li, Li; Meng, Xiao‐Ming; Huang, Cheng; Zhang, Lei; Deng, Zhiping; Li, Jun

doi:10.1186/s12943-018-0852-7

Cited by 41 publications

(30 citation statements)

References 104 publications

(131 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, DLX6-AS1 had a high expression high level in prostate cancer, and its silencing restricted cell proliferation, migration, and invasion of prostate cancer cells in vitro as well as lymph node metastasis in vivo. The involvement of lncRNAs in the tumorigenesis, metastasis, and prognosis or diagnosis of prostate cancer has been highlighted in a previous study (15). Consistent with present findings, the level of DLX6-AS1 was upregulated in gastric cancer, where DLX6-AS1 also promotes cell proliferation, migration and EMT (16).…”

Section: Discussionsupporting

confidence: 92%

RETRACTED: LncRNA DLX6-AS1 Promotes Malignant Phenotype and Lymph Node Metastasis in Prostate Cancer by Inducing LARGE Methylation

2020

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) have recently become recognized as crucial players in cancer cellular events including proliferation, migration, and invasion. Herein, we investigated the potential role of lncRNA DLX6-AS1 in prostate cancer cell malignant behaviors and lymph node metastasis. A differentially expressed lncRNA DLX6-AS1 and its downstream regulatory gene (LARGE) were predicted by analysis in silico. RT-qPCR and western blot analysis results demonstrated that DLX6-AS1 was highly expressed, but LARGE was poorly expressed in prostate cancer tissues and cells. The online website indicated that DLX6-AS1 negatively targeted LARGE expression, which was validated by Pearson correlation analysis and MSP. ChIP, RIP, and RNA pull-down assays further suggested that DLX6-AS1 downregulated LARGE expression through recruitment of DNMT1 to its promoter. We induced DLX6-AS1/LARGE overexpression or knockdown to examine their effects through Edu and Transwell assays, which revealed that DLX6-AS1 overexpression accelerated proliferation, invasion, and migration of prostate cancer cells, and that overexpression of LARGE rescued these effects. Tumors xenografts studies confirmed that DLX6-AS1 promoted lymph node metastasis by regulating LARGE, as evidenced by enhanced expression of MMP-9, uPAR, and cathepsin B. In summary, DLX6-AS1 stimulated prostate cancer malignant progression and lymph node metastasis by inducing DNMT1-mediated LARGE methylation, highlighting a potential therapeutic target against prostate cancer.

show abstract

Section: Discussionsupporting

confidence: 92%

RETRACTED: LncRNA DLX6-AS1 Promotes Malignant Phenotype and Lymph Node Metastasis in Prostate Cancer by Inducing LARGE Methylation

2020

View full text Add to dashboard Cite

show abstract

“…Although aggressive treatments, such as maximal resection, adjuvant radiotherapy, and chemotherapy are used for patients with GBM, the survival rate is still difficult to improve, 15 due to the poor understanding of the pathogenesis of GBM and the lack of an effective therapeutic target. Previous studies have reported that differential genes play an important role in the pathology of tumors and may be potential therapeutic targets 16–18 . To understand and identify potential therapeutic targets in GBM, we explored the mechanisms underlying the pathogenesis of GBM in this study.…”

Section: Discussionmentioning

confidence: 99%

Construction of lncRNA‐associated ceRNA networks to identify prognostic lncRNA biomarkers for glioblastoma

Liu

Wang

Yang

et al. 2020

J of Cellular Biochemistry

View full text Add to dashboard Cite

Long noncoding RNAs (lncRNAs) serve as competitive endogenous RNAs (ceRNAs) that play significant regulatory roles in the pathogenesis of tumors. However, the role of lncRNAs, especially the lncRNA-related ceRNA regulatory network, in glioblastoma (GBM) has not been fully elucidated. The goal of the current study was to construct lncRNA-microRNA-mRNA-related ceRNA networks for further investigation of their mechanism of action in GBM. We downloaded data from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) databases and identified differential lncRNAs, microRNAs (miRNAs), and messenger RNAs (mRNAs) associated with GBM. A ceRNA network was constructed and analyzed to examine the relationship between lncRNAs and patients' overall survival. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGGs) were used to analyze the related mRNAs to indirectly explain the mechanism of action of lncRNAs. The potential effective drugs for the treatment of GBM were identified using the connectivity map (CMap). After integrated analysis, we obtained a total of 210 differentially expressed lncRNAs, 90 differentially expressed miRNAs, and 2508 differentially expressed mRNAs (DEmRNAs) from the TCGA and GEO databases. Using these differential genes, we constructed a lncRNA-associated ceRNA network. Six lncRNAs in the ceRNA network were associated with the overall survival of patients with GBM. Through KEGG analysis, it was found that the DEmRNAs involved in the network are related to cancer-associated pathways, for instance, mitogen-activated protein kinase and Ras signaling pathways. CMap analysis revealed four small-molecule compounds that could be used as drugs for the treatment of GBM. In this study, a multi-database joint analysis was used to construct a lncRNA-related ceRNA network to help identify the regulatory functions of lncRNAs in the pathogenesis of GBM.

show abstract

“…Next-generation sequencing technologies have identified more than 58,000 lncRNAs among human transcriptome, while the number of protein-coding genes is only 21,000 [16]. A variety of lncRNAs are revealed to be deregulated and associated with patients' prognosis in several cancers including cervical cancer [17][18][19][20]. Furthermore, many lncRNAs are shown to regulate various biological aspects of cancer cells, such as cell proliferation, apoptosis, cell cycle, migration, invasion, drug-resistance, and so on [21][22][23].…”

mentioning

confidence: 99%

Long non-coding RNA DANCR promotes cervical cancer growth via activation of the Wnt/β-catenin signaling pathway

et al. 2020

View full text Add to dashboard Cite

Background: Long non-coding RNAs (lncRNAs) are implicated in many pathophysiological processes, including cancers. In particular, lncRNA DANCR is regarded as a cancer-associated lncRNA exerting various regulatory mechanisms. However, the expressions, functions, and mechanisms of action of DANCR in cervical cancer are still unclear. Methods: The expressions of DANCR in cervical cancer tissues and cell lines were evaluated using qRT-PCR. Correlations between DANCR expression and clinicopathological features and prognosis were analyzed. The roles of DANCR in cervical cancer growth were evaluated by in vitro CCK-8 and EdU assay, and in vivo xenograft assay. The regulatory effects of DANCR on Wnt/β-catenin signaling pathway were evaluated using nuclear proteins extraction, western blot, and qRT-PCR. Results: DANCR is increased in cervical cancer tissues and cell lines. Increased expression of DANCR is associated with large tumor size, advanced FIGO stage, and poor overall survival of cervical cancer patients. Functional experiments showed that enhanced expression of DANCR promotes cervical cancer cell proliferation in vitro and xenograft growth in vivo. Conversely, DANCR knockdown inhibits cervical cancer cell proliferation in vitro and xenograft growth in vivo. Mechanistic investigation demonstrated that DANCR upregulates the expressions of FRAT1 and FRAT2 and activates the Wnt/β-catenin signaling pathway. Blocking the Wnt/β-catenin signaling pathway abolishes the proproliferative roles of DANCR overexpression and anti-proliferative roles of DANCR knockdown. Conclusions: Our findings suggest DANCR as an oncogenic lncRNA in cervical cancer through activating the Wnt/βcatenin signaling pathway, and imply that DANCR may be a promising prognostic biomarker and therapeutic target for cervical cancer.

show abstract

Pathological bases and clinical impact of long noncoding RNAs in prostate cancer: a new budding star

Cited by 41 publications

References 104 publications

RETRACTED: LncRNA DLX6-AS1 Promotes Malignant Phenotype and Lymph Node Metastasis in Prostate Cancer by Inducing LARGE Methylation

RETRACTED: LncRNA DLX6-AS1 Promotes Malignant Phenotype and Lymph Node Metastasis in Prostate Cancer by Inducing LARGE Methylation

Construction of lncRNA‐associated ceRNA networks to identify prognostic lncRNA biomarkers for glioblastoma

Long non-coding RNA DANCR promotes cervical cancer growth via activation of the Wnt/β-catenin signaling pathway

Contact Info

Product

Resources

About